Description

The Hepatic Fibrosis Test YRA317 and YRA321 are advanced diagnostic tools specifically designed for the early detection and monitoring of liver fibrosis, a critical step in avoiding the progression to cirrhosis. Engineered to work seamlessly with Chemiluminescence Immunoassay Analyzers YR06389 and YR06390, these tests assure accuracy and reliability in results. They analyze important biomarkers such as PIIINP and CG, providing a comprehensive assessment of liver health, which allows for timely intervention that can substantially enhance a patient’s quality of life and prognosis.

Market Price

The market range for hepatic fibrosis tests like the YRA317 and YRA321 can fluctuate depending on factors such as regional pricing, supplier variations, and purchase volumes. Although specific pricing is not listed here, potential buyers can secure the most competitive deal by requesting a quotation through our Kalstein Plus platform, ensuring access to value pricing and exemplary service.

Frequently Asked Questions

What is the shelf life of the Hepatic Fibrosis Test kits? These kits maintain stability when stored between 2-8°C, and remain effective up to the expiration date displayed on their packaging.

Can these tests be used with any other equipment? The Hepatic Fibrosis Tests YRA317 and YRA321 are specifically tailored for optimal performance with the Chemiluminescence Immunoassay Analyzers YR06389 and YR06390.

Advantages and Disadvantages

The primary advantage of these tests lies in their capability to detect liver fibrosis early, which is crucial for effective treatment and disease management. They are compatible with state-of-the-art analyzers and adhere to high certification standards such as CE and ISO13485. On the downside, the requirement for their specific analyzer equipment may limit utility to facilities that possess these devices.

Field Use

These tests are predominantly employed in hospitals and laboratories for precise liver health monitoring, particularly in patient demographics susceptible to liver damage due to conditions like hepatitis or alcohol consumption. The insights gathered from these tests enable healthcare providers to devise customized treatment strategies to effectively manage liver fibrosis.

Recommendations

To obtain the maximum benefit from the Hepatic Fibrosis Test, it is crucial to comply with storage guidelines and equipment compatibility requirements. Regular calibration and maintenance of the Chemiluminescence Immunoassay analyzers are vital for ensuring ongoing accuracy. The results of these tests should inform ongoing treatment plan adjustments, and further professional advice should be sought as necessary. For a smooth purchasing experience, visit our Kalstein Plus platform to quickly generate a quote.

Features

• Early detection and monitoring of liver fibrosis.
• Compatibility with YR06389 and YR06390 analyzers.
• CE, ISO13485, and FSC certified.
• Comprehensive parameter analysis including PIIINP, CIV, LN, HA, and CG.

Technical Specifications